Posters

XEN45 Gel Stent implant: outcomes of XEN implantation alone vs combined phacoemulsification-XEN surgery

Poster Details

First Author: N.Moura-Coelho PORTUGAL

Co Author(s):    S. Crisostomo   L. Costa   A. Basi�Â�­lio   M. Dutra-Medeiros   M. Sa Cardoso   T. Gomes     

Abstract Details

Purpose:

To evaluate and compare efficacy and safety of the XEN45 Gel Stent Glaucoma Treatment System (Allergan, Irvine, CA) implantation alone versus the combined Xen implantation and phacoemulsification (Phaco-Xen) in patients with medically refractory open-angle glaucoma (OAG).

Setting:

The study was conducted at a tertiary center for Ophthalmology in Portugal, reporting the initial experience with XEN implantation at the national level.

Methods:

Retrospective review of 19 eyes of 18 patients with OAG that underwent surgery at our institution, either Xen implant alone or combined Phaco-Xen. Clinical outcomes compared at 6-month follow-up included intra-ocular pressure (IOP) reduction, rate of IOP reduction, reduction in number IOP-lowering drug requirements, required additional procedures, and complications.

Results:

11 eyes underwent Xen implant alone, and 8 eyes underwent combined Phaco-Xen surgery. A significant reduction in IOP at 6-month post-surgery was observed in both Xen and Phaco-Xen patient groups (p-value = 0.019, p-value = 0.050, respectively). The median difference in IOP reduction between both groups was not statistically significant (p-value = 0.741), as were not the median rate of IOP reduction and the median reduction in IOP-lowering drug requirements post-operatively (p-value = 0.934 and p-value = 0.448, respectively). No major intra-operative or post-operative complications were observed; 3 patients in each group required additional procedures within the follow-up period.

Conclusions:

In this study, XEN surgery showed good efficacy in IOP reduction and safety profiles in medically refractory open-angle glaucoma, either alone or combined with cataract surgery. Larger, prospective studies are encouraged to further assess whether associating cataract surgery to Xen implantation may have an added IOP-lowering benefit.

Financial Disclosure:

NONE